COMP <GO>
IRMD vs ABBV // PIOTROSKI F-SCORE QUALITY
iRadimed Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IRMD 8
— ABBV 4
▲ PIOTROSKI F-SCORE QUALITY LEADER: IRMD
LAST: $85.74 (+2.16%) • MKT CAP: $1.10B
piotroski-score
8/9
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.70% | 70.20% | +6.50 | IRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 37.70% | 29.00% | +8.70 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.9x | 33.3x | -1.40 | IRMD | /valuation <GO> |
| Free Cash Flow Yield | 1.57% | 3.47% | -1.90 | ABBV | /fcf-yield <GO> |
| Operating Margin | 31.20% | 24.60% | +6.60 | IRMD | /operating-margins <GO> |
| Net Profit Margin | 26.80% | 6.90% | +19.90 | IRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 14.40% | 8.60% | +5.80 | IRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.37% | 2.27% | -0.90 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | IRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 65.1 | -15.00 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.0x | 113.1x | -72.10 | IRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.10B | $513.86B | -$512.76B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRMD REV | ABBV REV | IRMD GROSS % | ABBV GROSS % | IRMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $83.8M | $61.16B | 76.7% | 70.2% | $17.2M | $17.82B |
| FY 2024 | $73.2M | $56.33B | 76.9% | 70.0% | $17.6M | $17.83B |
| FY 2023 | $65.6M | $54.32B | — | — | $13.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
ABBV // BETA 1.15